E-DRUG: Independent Drug & Healthcare Newsletter for April 2017
----------------------------------------------------------------------------------
Newsletter, April 2017
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
N° 181 April 2017
View the table of contents for the current issue
Subscribe to Prescrire International
In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis. For selected patients, with cardiac monitoring
FEATURED REVIEW Despite delamanid's rather shaky evaluation, the available data suggest that this antibiotic should be offered to patients with multidrug-resistant tuberculosis.
The noteworthy impact of delamanid on the QT interval warrants electrocardiographic monitoring and close attention to drug interactions.
Full review (4 pages) available for download by subscribers.
Read more
--------------------------------------------------------------------------------
In the April issue of Prescrire International: unborn children still exposed to NSAIDs
FREE DOWNLOAD
In the Adverse Effects section of the April edition: results of a French study showing that around 5% of unborn children in France are exposed to prescribed NSAIDs, including about 1% from the 6th month of pregnancy. And these numbers exclude self-medication.
Authorities need to send out a stronger message:
"NEVER USE NSAIDs DURING PREGNANCY".
Full text available for free download.
Read more
--------------------------------------------------------------------------------
Protelos° (strontium ranelate) ought to have been withdrawn from the market long ago
In early March 2017, drug company Servier announced that it would be withdrawing its strontium ranelate-based Protelos° from the market. This withdrawal comes after far too much foot-dragging, which was positive for the company but harmful for patients. Considering its efficacy, modest at best, and its disproportionate adverse effects, strontium ranelate ought to have been withdrawn from the market long ago.
Read more
--------------------------------------------------------------------------------
Knowing how to say "No thank you" is crucial
Being able to say "no thank you" to firms seeking to influence healthcare professionals is crucial to obtaining information and training that prioritises patients' best interests. It is also crucial when choosing a drug, especially when that drug does more harm than good and exposes patients to disproportionate risks.
Read more
--------------------------------------------------------------------------------
Bone fragility: preventing fractures
The prevention of fractures associated with bone fragility is based on fall prevention and regular physical activity, and drug therapy only in some cases.
Read more
--------------------------------------------------------------------------------
Prescrire's "Non merci" Charter: saying "No thank you" to conflicts of interest
ABOUT PRESCRIRE Prescrire's pioneering "Non merci..." Charter guarantees that Prescrire's editors and managers are free from any conflicts of interest.
Read more
Share this with a friend or colleague: Forward this email
Get this from a friend? Sign up here
Prescrire International <international@prescrire.org>